The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis

The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis

Abstract Background Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its characteristic and prognosis value in hormonal sensitive prostate cancer is uncl...

Full description

Bibliographic Details
Main Authors:	Zhize Wang, Haixiang Shen, Zhen Liang, Yeqing Mao, Chaojun Wang, Liping Xie
Format:	Article
Language:	English
Published:	BMC 2020-05-01
Series:	Cancer Cell International
Subjects:	Androgen receptor splicing variant 7 First-line hormonal therapy Prostatectomy Prostate cancer Predictor Survival
Online Access:	http://link.springer.com/article/10.1186/s12935-020-01229-4

Similar Items

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
by: Zhize Wang, et al.
Published: (2020-11-01)

Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
by: Qinchen Li, et al.
Published: (2021-09-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Therapeutic Approaches to Targeting Androgen Receptor Splice Variants
by: Violet A. Daniels, et al.
Published: (2024-01-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Jiaxin Wang, et al.
Published: (2020-11-01)

Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016-05-01)

Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development
by: Kimberley D. Katleba, et al.
Published: (2023-08-01)

Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
by: Mercedes Marín-Aguilera, et al.
Published: (2020-01-01)

Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer
by: Tryambak Pratap Srivastava, et al.
Published: (2024-11-01)

The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
by: Sepehr Torabinejad, et al.
Published: (2023-05-01)

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
by: Naoya Nagaya, et al.
Published: (2020-04-01)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
by: Michael W. Kattan, et al.
Published: (2020-11-01)

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
by: Bohan Ma, et al.
Published: (2022-10-01)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
by: Farhan Khan, et al.
Published: (2023-02-01)

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
by: Elisabeth A. Messner, et al.
Published: (2020-10-01)

Comparison of Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variant 1 in Different Stages of Endometriosis
by: Qiming Wang, et al.
Published: (2013-04-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers
by: Juan Guzman, et al.
Published: (2024-03-01)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2015-09-01)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2018-04-01)

The Expression of Androgen Receptor and Its Variants in Human Prostate Cancer Tissue according to Disease Status, and Its Prognostic Significance
by: Sung-Woo Park, et al.
Published: (2019-01-01)

The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis
by: Shankun Zhao, et al.
Published: (2023-02-01)

A novel biguanide derivative, IM176, induces prostate cancer cell death by modulating the AMPK-mTOR and androgen receptor signaling pathways
by: Yunlim Kim, et al.
Published: (2023-06-01)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
by: Anieta M. Sieuwerts, et al.
Published: (2019-08-01)

Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer
by: Sean Seltzer, et al.
Published: (2023-01-01)

Differential Expression of the Androgen Receptor, Splice Variants and Relaxin 2 in Renal Cancer
by: Joanna Bialek, et al.
Published: (2021-07-01)

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
by: Marta Garcia de Herreros, et al.
Published: (2024-12-01)

Knowledge structure and emerging trends of AR variants in prostate cancer: a bibliometric analysis based on CiteSpace and VOSviewer
by: Kai Yu, et al.
Published: (2023-07-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020-01-01)

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer
by: Hyun-Kyung Ko, et al.
Published: (2018-01-01)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
by: Jun Luo
Published: (2016-01-01)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022-11-01)

SUBSTITUTION ANDROGEN THERAPY AFTER RADICAL TREATMENT OF PROSTATE CANCER
by: T. Kh. Nazarov, et al.
Published: (2018-05-01)

Androgen receptor inhibitors in treating prostate cancer
by: Ryan N Cole, et al.
Published: (2025-03-01)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
by: Yongbao Wei, et al.
Published: (2023-10-01)

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
by: Gaetano Aurilio, et al.
Published: (2020-12-01)

Frailty of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review
by: Jeongok Park, et al.
Published: (2024-04-01)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
by: Satoru Ueno, et al.
Published: (2018-03-01)